REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
12 hedge funds and large institutions have $12.8M invested in REVIVA PHARMA HLDGS INC in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
280% more capital invested
Capital invested by funds: $3.37M → $12.8M (+$9.41M)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
50% more funds holding
Funds holding: 8 → 12 (+4)
22.38% more ownership
Funds ownership: 6.35% → 28.74% (+22%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.05M |
| 2 |
AC
Armistice Capital
New York
|
+$3.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.67M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$341K |
| 5 |
BlackRock
New York
|
+$92.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$210K |
| 3 |
Millennium Management
New York
|
-$203K |
| 4 |
DC
Davenport & Co
Richmond,
Virginia
|
-$25.2K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$17K |
RVPH Hedge Fund Activity: Q2 2021 in Review
12 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q2 2021, worth a combined $12.8M — up 280% from $3.37M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RVPH positions and 4 closed out — a net gain of 4 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $6.05M. The largest seller was Sabby Management, exiting entirely with an estimated $2.4M sold.
- 12 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q2 2021, up from 8 in Q1 2021.
- Funds reported $12.8M of REVIVA PHARMA HLDGS INC stock for Q2 2021, up 280% quarter-over-quarter.
- 8 funds opened new REVIVA PHARMA HLDGS INC positions in Q2 2021 and 4 closed out, a net change of +4 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q2 2021 was Tang Capital Management, an estimated $6.05M added.
- The largest REVIVA PHARMA HLDGS INC seller in Q2 2021 was Sabby Management, an estimated $2.4M sold.
Based on aggregated 13F filings for Q2 2021.